Propanc Biopharma (OTCMKTS:PPCB) Stock Price Down 4% – What’s Next?

Propanc Biopharma Inc (OTCMKTS:PPCB) shares traded down 4% during mid-day trading on Wednesday . The company traded as low as $0.2006 and last traded at $0.2015. 316,130 shares traded hands during trading, a decline of 84% from the average session volume of 1,929,584 shares. The stock had previously closed at $0.21.

Propanc Biopharma Stock Performance

The company has a quick ratio of 2.24, a current ratio of 2.24 and a debt-to-equity ratio of 0.01. The company’s 50-day moving average is $0.37 and its two-hundred day moving average is $1.43. The company has a market capitalization of $3.20 million, a P/E ratio of -0.02 and a beta of 3.66.

Institutional Trading of Propanc Biopharma

A hedge fund recently bought a new stake in Propanc Biopharma stock. Virtu Financial LLC bought a new position in Propanc Biopharma Inc (OTCMKTS:PPCB) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 41,677 shares of the company’s stock, valued at approximately $71,000. Virtu Financial LLC owned approximately 0.33% of Propanc Biopharma as of its most recent filing with the Securities & Exchange Commission.

Propanc Biopharma Company Profile

Propanc Biopharma Ltd is a clinical-stage biotechnology company focused on developing novel biologic drug candidates for the treatment of invasive and metastatic cancers. The company’s core technology centers on proprietary formulations of recombinant human proteolytic enzymes designed to degrade the dense extracellular matrix that surrounds solid tumors. By reducing stromal barriers, these candidates are intended to enhance the delivery and efficacy of co-administered chemotherapies, immunotherapies or other targeted agents.

The company’s lead program, known as PRP, comprises a combination of modified pancreatic proteases that have demonstrated promising preclinical activity in degrading tumor stroma and inhibiting tumor growth.